Together,
we can reach higher ground
At Climb Bio, we believe elevating relationships leads to more meaningful insights, better answers, and ultimately, to more inspired medicines for patients living with immune-mediated diseases.
Experienced team
At Climb Bio, our team has a knack for seeing what no one else sees—and a drive to achieve results no one expects.
Aoife Brennan, M.B., Ch.B.
President and Chief Executive Officer
Jan Hillson, M.D.
Senior Clinical Advisor
Brett Kaplan, M.D.
Chief Operating Officer
William Bonificio, Ph.D.
Interim Chief Business Officer
Emily Pimblett, CPA
Chief Accounting Officer
Nishi Rampal, M.D.
Senior Vice President, Clinical Development
Kate Hecht, MBA
Senior Vice President, Program Management
Janaki M. Subramanyam, MSc, RAC
Vice President, Head of Regulatory Affairs
Jay Mitchell, MBA
Vice President, Clinical Operations
Elevating possibilities
Our pipeline is focused on immune-mediated diseases, including advancing budoprutug, an anti-CD19 antibody designed for a broad range of B-cell mediated diseases.
CANDIDATE
Budoprutug
Anti-CD19
Fc-engineered, monoclonal antibody
Indications
Membranous Nephropathy
Phase 1
Systemic Lupus Erythematosus*
Phase 1
Immune Thrombocytopenia*
Phase 1
Commitment to patients
We only have one life to live. At Climb, we all feel the urgency to give everyone living with an immune-mediated disease more quality time—and less time thinking of themselves as a patient.
Come climb with us
Here you’ll find good people. Smart people. Curious people. Our team has a diversified past, a singular focus on the now, and an unshakeable commitment to a better future.
OPEN POSITIONS: